Clinical Research Directory
Browse clinical research sites, groups, and studies.
QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)
Sponsor: Qilu Pharmaceutical Co., Ltd.
Summary
This Phase III clinical trial aims to assess the efficacy and safety of QLC7401 Treatment in adults with Heterozygous Familial Hypercholesterolemia on a stable lipid-lowering therapy. Participants will be randomly assigned to receive subcutaneous injections of either QLC7401 or a placebo according to the study schedule.
Official title: Evaluation of Efficacy and Safety of QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia on a Stable Lipid-lowering Therapy: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2026-05
Completion Date
2028-07
Last Updated
2026-03-04
Healthy Volunteers
No
Interventions
QLC7401 Injection
QLC7401 is a small interfering RNA (siRNA) targeting PCSK9. Administered as subcutaneous injection at a specified dose level.
Placebo
Placebo matching QLC7401 in appearance and administration.